A prospective cohort study of safety and Immunogenicity of inactivated COVID-19 vaccine and virus vector vaccine in Thai adults A prospective cohort study of safety and Immunogenicity of inactivated COVID-19 vaccine and virus vector vaccine in Thai adults
Conditions
Interventions
Thai adults between 18-59 years who received inactivated COVID-19 Vaccine
Sinovac (CoronaVac), China.,Thai adults aged above 18 years who received AstraZeneca virus vector COVID-19 vaccine.
Prevention,Prevention
Sinovac,AstraZeneca
Sponsors
National Research Council, TH
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Healthy Thai adults aged between 18-60 years 2. Willing to be immunized with COVID-19 vaccine 3. Intend to be available for follow-up visits and phone call through 12 months postvaccination
Exclusion criteria
Exclusion criteria: 1. Subjects with history of COVID-19, asymptomatic SARS-CoV-2 infection or pre-existing antibodies to SARS-CoV-2 2. Previous severe reaction or allergy to any components in the COVID-19 vaccine 3. History of hospitalization within the past one month before injection. 4. Serious underlying medical condition (e.g., immunosuppressive disease or receiving immunosuppressive therapy, human immunodeficiency virus (HIV) infection) 5. Pregnant women, lactating women or women who are planning to become pregnant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity antibody titers antibody titers | — |
Secondary
| Measure | Time frame |
|---|---|
| safety 7 days after vaccination adverse event record booklet | — |
Countries
Thailand
Contacts
Public ContactNasamon Wanlapakorn
Chulalongkorn University
Outcome results
None listed